The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.
about
Ibrutinib: Implications for Use in the Treatment of Mantle Cell Lymphoma and Chronic Lymphocytic LeukemiaBCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic LeukemiaThe role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemiaA hostel for the hostile: the bone marrow niche in hematologic neoplasmsPI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL)Targeted Therapies in Adult B-Cell MalignanciesTargeting chronic lymphocytic leukemia cells in the tumor microenviroment: A review of the in vitro and clinical trials to dateThe B-cell receptor orchestrates environment-mediated lymphoma survival and drug resistance in B-cell malignanciesTargeting the B-cell receptor signaling pathway in B lymphoid malignanciesThe outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergyBruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomasBruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinibB cell receptor pathway in chronic lymphocytic leukemia: specific role of CC-292How will B-cell-receptor-targeted therapies change future CLL therapy?Targeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisibSynergistic Activity of Deguelin and Fludarabine in Cells from Chronic Lymphocytic Leukemia Patients and in the New Zealand Black Murine ModelTherapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemiaIbrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axisDasatinib inhibits CXCR4 signaling in chronic lymphocytic leukaemia cells and impairs migration towards CXCL12Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphomaTargeting Btk/Etk of prostate cancer cells by a novel dual inhibitorUpdate on chronic lymphocytic leukemia: overview of new agents and comparative analysis.Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trialIbrutinib: a new frontier in the treatment of chronic lymphocytic leukemia by Bruton's tyrosine kinase inhibitionUnification of de novo and acquired ibrutinib resistance in mantle cell lymphoma.Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphomaThe pathogenic relevance of the prognostic markers CD38 and CD49d in chronic lymphocytic leukemiaPI3Kδ inhibition elicits anti-leukemic effects through Bim-dependent apoptosisInhibition of BTK protects lungs from trauma-hemorrhagic shock-induced injury in ratsBruton's tyrosine kinase promotes persistence of mature anti-insulin B cells.Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach.Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib.Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapyEgress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.Bruton's tyrosine kinase (BTK) inhibitors in clinical trials.BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future.Ibrutinib inhibits SDF1/CXCR4 mediated migration in AMLInhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma.Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.
P2860
Q26749010-9BFEA713-A393-49DF-8482-8E38C5890418Q26765624-DEE700D0-C896-49BB-B0DF-26E71985317CQ26775506-8F132A98-1D1D-44B7-AEB1-AE2D832F759DQ26777629-24DF6CCD-4C82-4C31-8E9E-D0594F575C7FQ26782633-4DE047E3-A004-46AC-977B-B1741CD5037BQ26783195-37D3BCFA-B8BA-4A1F-A292-CD8C026ED06CQ26798062-01632B36-F089-46FA-B9D0-B320E27EF950Q26822700-3B482132-7965-48ED-8FB5-DC6CDB63690AQ26828782-90A95981-CB69-4644-B8CE-F62379FA5062Q26865760-41F26D1C-A154-4A85-974E-AD2B68196E6BQ26991890-1DF0BF89-3AC8-4D83-B64E-67CAB44A4C78Q26995113-6A27E85C-6DA9-4906-9860-67597D236C3DQ27009550-443833BA-8910-450E-B1BA-8B29A7FFD19AQ27024187-4C4F55D4-BF51-4A20-8879-1B9735EEDDA7Q27025812-BBDDBB6E-76E8-4ACA-AFC4-9F23FD31C4D7Q27312452-7468FF22-5046-4B9F-BD35-20A6DD4FDD05Q28087378-DA66E901-C1FF-4037-8265-F6CC80310FB2Q28277551-FD9E74D3-CA10-497B-8F3C-897D5BFAF35AQ28484839-D62D530E-7A7A-4CD1-B22B-A64BABB98FE3Q30371806-524215A2-82BB-4A1D-B4FE-3255459C8651Q30661625-BE507B1E-DF53-4084-A55E-6F0FBD428271Q33406478-72BDFA2F-7DFE-434A-905E-568ACD9DBF23Q33412064-58FC6670-AB29-493B-8DB6-C3DCF6DF4E9BQ33566063-BB66C56F-9474-47DC-BBF7-C06DDCF0C340Q33587128-5657D184-B9D3-4E27-87CC-268327D7CCEAQ33587826-DC8A931A-586B-4732-BA89-A17EAEB3295EQ33655756-16FCC510-C9CF-40A1-AC7D-F8771BF279D5Q33785941-ECF247BA-BDA6-46AD-AC18-3F97D98C5137Q33827989-8C58DF51-7411-4AC7-B198-AC50E93593B1Q33852815-AC2CEB67-3DFB-4F11-A3FA-F50726D0B1FAQ33893704-1951366F-A957-4CC9-B281-E69A1C8A9332Q33924158-A921CF32-2B50-438C-9C7E-EB29AE159155Q34009064-24D5E0C6-6264-4D8F-89A8-F36E9C35CE29Q34020276-0C925829-0E8C-42A5-9B2F-06F7D1387594Q34037828-7D1E2998-D63D-463E-9566-B05B73FE46A3Q34039406-59C943BE-A274-46ED-A6FF-FD2A3C325EBBQ34041311-9C747F11-78D2-47AB-9B84-E47FDF779BC3Q34042250-28BE2382-CA9F-4064-BD5B-4F0CAF5DD5E6Q34042407-24AE2FC2-E7CD-4D75-A8C2-38ECDBF032E5Q34172063-7F44A3CF-511C-4402-845E-D8ECAFD6AED9
P2860
The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
The clinically active BTK inhi ...... chronic lymphocytic leukemia.
@ast
The clinically active BTK inhi ...... chronic lymphocytic leukemia.
@en
The clinically active BTK inhi ...... chronic lymphocytic leukemia.
@nl
type
label
The clinically active BTK inhi ...... chronic lymphocytic leukemia.
@ast
The clinically active BTK inhi ...... chronic lymphocytic leukemia.
@en
The clinically active BTK inhi ...... chronic lymphocytic leukemia.
@nl
prefLabel
The clinically active BTK inhi ...... chronic lymphocytic leukemia.
@ast
The clinically active BTK inhi ...... chronic lymphocytic leukemia.
@en
The clinically active BTK inhi ...... chronic lymphocytic leukemia.
@nl
P2093
P1433
P1476
The clinically active BTK inhi ...... chronic lymphocytic leukemia.
@en
P2093
Annemieke Kuil
Betty Y Chang
Christian R Geest
Eric Eldering
Joseph J Buggy
Martin F M de Rooij
Steven T Pals
P304
P356
10.1182/BLOOD-2011-11-390989
P407
P577
2012-01-25T00:00:00Z